NIKKEI 225
28,594.31 -210.54 (-0.73%) HANG SENG
26,146.03 +19.10 (+0.07%) GOLD FUTURES
1,799.60 +3.30 (+0.18%) DOW
35,677.02 +73.92 (+0.21%) BTC-GBP
44,913.62 +438.57 (+0.99%) CMC Crypto 200
1,453.34 -49.70 (-3.31%)
Roche Holding AG (RHHBY)
| Previous close | 48.84 |
| Open | 48.26 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 48.00 - 48.79 |
| 52-week range | 39.72 - 51.05 |
| Volume | 1,020,097 |
| Avg. volume | 1,015,185 |
| Market cap | 338.98B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 21.68 |
| EPS (TTM) | 2.25 |
| Earnings date | N/A |
| Forward dividend & yield | 1.22 (2.60%) |
| Ex-dividend date | 18 Mar 2021 |
| 1y target est | 52.44 |
- Globe Newswire
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. This is the first time that research scientists can conduct oncology research with Foundation Medicine’s comprehensive genomic profiling in their own laboratories to gain meaningful genomic insights and deepen their understanding of cancer biology. This kit is an importan
- Motley Fool
Why Atea Pharmaceuticals Stock Got Crushed This Week
Shares of the clinical-stage biotech Atea Pharmaceuticals (NASDAQ: AVIR) closed the week down by a whopping 68.6%, according to data from S&P Global Market Intelligence. The biotech's stock plummeted last Tuesday after announcing that its oral antiviral pill, known as AT-527, badly missed the mark in a phase 2 trial called MOONSONG for patients with mild or moderate cases of COVID-19. AT-527 is being co-developed with pharma heavyweight Roche (OTC: RHHBY).
- Reuters
Roche's implant for chronic eye disorder wins U.S. approval
(Reuters) -Roche Holding AG on Friday won approval from the U.S. health regulator for its eye implant to treat a chronic disorder causing blurred vision, giving patients an alternative to receiving monthly eye injections with existing treatments. The surgically implantable device Susvimo is intended to treat wet age-related macular degeneration (wet AMD), a disorder caused by the leak of fluid or blood from abnormal blood vessels into an area near the retina called the macula. The device is designed to continuously deliver a customized version of the Swiss company's drug ranibizumab, branded as Lucentis, which is an anti-vascular endothelial growth factor (anti-VEGF) therapy.
